API | elotuzumab

elotuzumab (empliciti) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA First in Class

AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH repoDB

Active Ingredient History

NOW

Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
elotuzumab

More Chemistry

Pharmacology

Mechanisms of Action:
- SLAM family member 7 (Homo sapiens) ^UniProt
- SLAM family member 7 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$1422.6100 - $2488.8600

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bms-901608 | elotuzumab | empliciti | huluc63 | immunoglobulin g1, anti-(human protein cs1) (human-mouse huluc63 heavy chain), disulfide with human-mouse huluc63 kappa-chain, dimer | immunoglobulin g1, anti-(human slam family member 7 (cd2-like receptor activating cytotoxic cells, cd319 antigen)), humanized mouse monoclonal huluc63 gamma-1 heavy chain (222-214')-disulfide with humanized mouse monoclonal huluc63 kappa light chain (228-228'';231-231'')-bisdisulfide dimer | pdl-063

Organizations (61)

Research & Development (61)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (1)

Multiple Myeloma

Experimental Indications - Clinical Trial Phases 1-4 (11)

Amyloidosis (Phase 2)

Hematopoietic Stem Cell Transplantation (Phase 2)

Immunoglobulin G4-Related Disease (Phase 2)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Plasma Cell (Phase 1/Phase 2)

Lymphoma (Phase 3)

Multiple Myeloma ()

Neoplasms ()

Polycythemia Vera (Phase 1)

Primary Myelofibrosis (Phase 1)

Smoldering Multiple Myeloma (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 61
# of Trial Organizations: 61

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue